Montopoli, M <br/><br/>
"Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.  [electronic resource] 

 -  Current cancer drug targets  Feb 2011 
 - 226-35 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5576 
<br/><br/><label>Standard No.: </label>10.2174/156800911794328501  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--metabolism<br/>Apoptosis--drug effects<br/>Carcinoma--drug therapy<br/>Cell Line, Tumor<br/>Cisplatin--metabolism<br/>Cytoplasmic Granules--drug effects<br/>DNA, Mitochondrial--genetics<br/>Drug Resistance, Neoplasm<br/>Female<br/>Glucose--metabolism<br/>Glutathione--metabolism<br/>Humans<br/>Inhibitory Concentration 50<br/>Lipid Metabolism--drug effects<br/>Membrane Potential, Mitochondrial--drug effects<br/>Mitochondria--drug effects<br/>Oligomycins--pharmacology<br/>Ovarian Neoplasms--drug therapy<br/>Oxidative Phosphorylation--drug effects<br/>Oxygen Consumption--drug effects<br/>Rotenone--pharmacology<br/>Uncoupling Agents--pharmacology